NCT06075225View on ClinicalTrials.gov

MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2026

Conditions
GVHDAcute Stem Cell Transplant Complications
Interventions
DRUG

Ruxolitinib

Ruxolitinib is asministrated with the dose of 5mg bid for 28 days. If no signs of aGvHD, the dose of ruxolitinib is gradually tapered within the following 16 days.

Trial Locations (1)

610041

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

Sichuan University

OTHER